Animal Drug Compounding Market Share Analysis Report, 2022-2030
According to Nova one advisor, the global Animal Drug Compounding market size is expected to hit around USD 4.0 billion by 2030 from valued at USD 2.9 billion in 2022 and growing at a CAGR of 8.0% from 2022 to 2030.
Increase in demand for companion animals, rise in the number of licensed veterinarians or pharmacists, and limited number of FDA-approved drug products for several species and conditions are anticipated to boost the global animal drug compounding market during the forecast period.
Intermittent drug shortages and commercial unavailability of FDA-approved drug products drive the need of compounded preparations within veterinary practice. In species such as zoo animals, laboratory animals, exotic pets, wildlife, aquaria, and non-food aquaculture animals, the use of compounded preparations is paramount. Additionally, regulatory bodies are in the process of considering the critical need of access to compounded preparations within these species, which is a key factor driving the market.
Drug compounding is a process of mixing, combining, and altering the ingredients for developing tailor-made medications for animals. Compounded animal drugs are manufactured by veterinarians and pharmacists. Drug compounding is also considered when there are no appropriate drugs available for the treatment of a sick animal. Pharmacists consider two ways for compounding an animal drug: extra-label drugs and bulk ingredients. Compounded drugs are economical and most viable options for pet owners without insurance.
Veterinarians offer medical care through compounded drugs for various animal species such as zoo animals, exotic animals, and wild animals. Compounded drugs deliver vital medications to a patient; however, these drugs are not approved by the U.S. FDA.
Report Scope of the Animal Drug Compounding Market
|
Report Coverage |
Details |
|
Market Size |
USD 4.0 Billion by 2030 |
|
Growth Rate |
CAGR of 8.0% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, Animal Type, Dosage Form, Route of Administration and Region, |
|
Companies Mentioned |
|
Ingredient Providers Helping Companies Innovate in Compounding for Exotic Animals
Companies in the animal drug compounding market are increasing efforts to maintain a full line of chemicals and supplies to support veterinary compounding. Letco Medical - a supplier of pharmaceutical ingredients, is gaining recognition for maintaining a formula database, which helps to find the right mixture for any animal. Manufacturers in the animal drug compounding market are working closely with ingredient suppliers who provide APIs, bases, flavors, and formulas that support veterinary compounding.
Manufacturers are focusing on quality assurance and compliance to stringent standards to bolster their credibility in the market landscape. Apart from dogs and cats, companies are increasing their compounding capabilities for horses, birds and other exotic animals that swim and fly.
Innovations in Veterinary-Anesthesia, Pain-Management Medications Boost Market Growth
Inorganic strategies, such as mergers and acquisitions are gaining prominence in the animal drug compounding market. Wedgewood Pharmacy - a PCAB-accredited compounding pharmacy has announced the acquisition of Wildlife Pharmaceuticals, Inc. and its subsidiary ZooPharm to leverage incremental opportunities with innovations in veterinary-anesthesia and pain-management medications.
Manufacturers in the animal drug compounding market are extending their care for resident wildlife, non-domestic species, companion animals, and captive exotic breeds. They are increasing efforts to develop teams, co-ordinate resources, and expand customer relationships to boost company credentials. Companies are focusing on research and development to advance in specialized medications for managing aquariums, wildlife management organizations, conservation facilities, and private ranches.
Flavored Suspensions, Custom Medications Aid in Easy Administration of Pets
Custom-compounded medications have become a fast-growing phenomenon in the animal drug compounding market. Erie Pharmacy is gaining popularity for its comprehensive product portfolio in custom oral capsules, flavored suspensions, and compounded tablets. Since compounded drugs can be a life-saving option for difficult to medicate pets, owners are seeking consultation from veterinarians for compounding and customizing the strength of medication doses.
Factory made medication in many cases do not suit cats and dogs. Hence, companies in the animal drug compounding market are offering custom services in drug development to alter the medications as per specific doses and formulations that are easier to administer in pets. The combination of several ingredients has led to innovations in easy to swallow oral capsules. Flavored suspensions are serving as palatable options for pets that involve flavor enhancers such as fish, beef, peanut butter, and banana, among others.
Animal Drug Compounding Market: Segmentation
Animal Drug Compounding Market: Regional Segmentation
Why are Animal Drug Compounding Providers Targeting the U.S. Market?
“High Animal-related Spending in the U.S.”
The U.S. dominated the North America animal drug compounding market in terms of market share of 88.9% in 2021, and is expected to retain its top position throughout the forecast period.
According to World Atlas data, in the U.S., one in three households owns a cat, with an average of 2.7 cats per cat-owning household. The total cat population in the country was estimated to be around 76.5 million. Interestingly, in 2019 Americans spent more than US$ 52.5 Bn on their pets.
High spending on animal care is set to result in high demand for animal treatment in the United States.
Some of the prominent players in the Animal Drug Compounding Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Animal Drug Compounding market
Product
Animal Type
Dosage Form
Route of Administration
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Global Animal Drug Compounding Market Analysis and Forecast, by Product
3.1. Introduction & Definition
3.2. Key Findings / Developments
3.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
3.3.1. Anti-infectives
3.3.1.1. Metronidazole
3.3.1.2. Ketoconazole
3.3.1.3. Other Antibiotics
3.3.2. Anti-inflammatory
3.3.2.1. Prednisolone
3.3.2.2. Tramadol
3.3.2.3. Other Anti inflammatory
3.3.3. CNS Agents
3.3.3.1. Potassium bromide
3.3.3.2. Gabapentin
3.3.3.3. Other CNS agents
3.3.4. GI Drugs
3.3.4.1. Apomorphine
3.3.4.2. Ursodiol
3.3.4.3. Cisapride
3.3.4.4. Other GI Drugs
3.3.5. Others
3.3.5.1. Methimazole
3.3.5.2. Other drugs
3.4. Market Attractiveness Analysis, by Product
4. Global Animal Drug Compounding Market Analysis and Forecast, by Animal Type
4.1. Introduction & Definition
4.2. Key Findings / Developments
4.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
4.3.1. Companion Animal
4.3.1.1. Dogs
4.3.1.2. Cats
4.3.1.3. Others
4.3.2. Livestock
4.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Animal Type
5. Global Animal Drug Compounding Market Analysis and Forecast, by Dosage Form
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
5.3.1. Capsule
5.3.2. Solution
5.3.3. Powders
5.3.4. Suspension
5.3.5. Others
5.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Dosage Form
6. Global Animal Drug Compounding Market Analysis and Forecast, by Route of Administration
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
6.3.1. Oral
6.3.2. Injectable
6.3.3. Topical
6.3.4. Rectal
6.3.5. Ocular
6.4. Global Animal Drug Compounding Market Attractiveness Analysis, by Route of Administration
7. Global Animal Drug Compounding Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Global Animal Drug Compounding Market Value (US$ Mn) Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Global Animal Drug Compounding Market Attractiveness Analysis, by Region
8. North America Animal Drug Compounding Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
8.2.1. Anti-infectives
8.2.1.1. Metronidazole
8.2.1.2. Ketoconazole
8.2.1.3. Other Antibiotics
8.2.2. Anti-inflammatory
8.2.2.1. Prednisolone
8.2.2.2. Tramadol
8.2.2.3. Other Anti inflammatory
8.2.3. CNS Agents
8.2.3.1. Potassium Bromide
8.2.3.2. Gabapentin
8.2.3.3. Other CNS agents
8.2.4. GI Drugs
8.2.4.1. Apomorphine
8.2.4.2. Ursodiol
8.2.4.3. Cisapride
8.2.4.4. Other GI Drugs
8.2.5. Others
8.2.5.1. Methimazole
8.2.5.2. Other drugs
8.3. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
8.3.1. Companion Animal
8.3.1.1. Dogs
8.3.1.2. Cats
8.3.1.3. Others
8.3.2. Livestock Animal
8.4. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
8.4.1. Capsule
8.4.2. Solution
8.4.3. Powders
8.4.4. Suspension
8.4.5. Others
8.5. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
8.5.1. Oral
8.5.2. Injectable
8.5.3. Topical
8.5.4. Rectal
8.5.5. Ocular
8.6. North America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
8.6.1. U.S.
8.6.2. Canada
9. Europe Animal Drug Compounding Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
9.2.1. Anti-infectives
9.2.1.1. Metronidazole
9.2.1.2. Ketoconazole
9.2.1.3. Other Antibiotics
9.2.2. Anti-inflammatory
9.2.2.1. Prednisolone
9.2.2.2. Tramadol
9.2.2.3. Other Anti inflammatory
9.2.3. CNS Agents
9.2.3.1. Potassium Bromide
9.2.3.2. Gabapentin
9.2.3.3. Other CNS agents
9.2.4. GI Drugs
9.2.4.1. Apomorphine
9.2.4.2. Ursodiol
9.2.4.3. Cisapride
9.2.4.4. Other GI Drugs
9.2.5. Others
9.2.5.1. Methimazole
9.2.5.2. Other drugs
9.3. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
9.3.1. Companion Animal
9.3.1.1. Dogs
9.3.1.2. Cats
9.3.1.3. Others
9.3.2. Livestock Animal
9.4. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
9.4.1. Capsule
9.4.2. Solution
9.4.3. Powders
9.4.4. Suspension
9.4.5. Others
9.5. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
9.5.1. Oral
9.5.2. Injectable
9.5.3. Topical
9.5.4. Rectal
9.5.5. Ocular
9.6. Europe Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
9.6.1. Germany
9.6.2. U.K.
9.6.3. France
9.6.4. Italy
9.6.5. Spain
9.6.6. Rest of Europe
10. Asia Pacific Animal Drug Compounding Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
10.2.1. Anti-infectives
10.2.1.1. Metronidazole
10.2.1.2. Ketoconazole
10.2.1.3. Other Antibiotics
10.2.2. Anti-inflammatory
10.2.2.1. Prednisolone
10.2.2.2. Tramadol
10.2.2.3. Other Anti inflammatory
10.2.3. CNS Agents
10.2.3.1. Potassium Bromide
10.2.3.2. Gabapentin
10.2.3.3. Other CNS agents
10.2.4. GI Drugs
10.2.4.1. Apomorphine
10.2.4.2. Ursodiol
10.2.4.3. Cisapride
10.2.4.4. Other GI Drugs
10.2.5. Others
10.2.5.1. Methimazole
10.2.5.2. Other drugs
10.3. Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
10.3.1. Companion Animal
10.3.1.1. Dogs
10.3.1.2. Cats
10.3.1.3. Others
10.3.2. Livestock Animal
10.4. Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
10.4.1. Capsule
10.4.2. Solution
10.4.3. Powders
10.4.4. Suspension
10.4.5. Others
10.5. Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
10.5.1. Oral
10.5.2. Injectable
10.5.3. Topical
10.5.4. Rectal
10.5.5. Ocular
10.6. Asia Pacific Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
10.6.1. China
10.6.2. Japan
10.6.3. India
10.6.4. Australia & New Zealand
10.6.5. Rest of Asia Pacific
11. Latin America Animal Drug Compounding Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Introduction
11.2.1. Key Findings
11.3. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
11.3.1. Anti-infectives
11.3.1.1. Metronidazole
11.3.1.2. Ketoconazole
11.3.1.3. Other Antibiotics
11.3.2. Anti-inflammatory
11.3.2.1. Prednisolone
11.3.2.2. Tramadol
11.3.2.3. Other Anti inflammatory
11.3.3. CNS Agents
11.3.3.1. Potassium Bromide
11.3.3.2. Gabapentin
11.3.3.3. Other CNS agents
11.3.4. GI Drugs
11.3.4.1. Apomorphine
11.3.4.2. Ursodiol
11.3.4.3. Cisapride
11.3.4.4. Other GI Drugs
11.3.5. Others
11.3.5.1. Methimazole
11.3.5.2. Other drugs
11.4. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
11.4.1. Companion Animal
11.4.1.1. Dogs
11.4.1.2. Cats
11.4.1.3. Others
11.4.2. Livestock Animal
11.5. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
11.5.1. Capsule
11.5.2. Solution
11.5.3. Powders
11.5.4. Suspension
11.5.5. Others
11.6. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
11.6.1. Oral
11.6.2. Injectable
11.6.3. Topical
11.6.4. Rectal
11.6.5. Ocular
11.7. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
11.7.1. Brazil
11.7.2. Mexico
11.7.3. Rest of Latin America
12. Middle East & Africa Animal Drug Compounding Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Introduction
12.2.1. Key Findings
12.3. Introduction
12.3.1. Key Findings
12.4. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Product, 2017–2030
12.4.1. Anti-infectives
12.4.1.1. Metronidazole
12.4.1.2. Ketoconazole
12.4.1.3. Other Antibiotics
12.4.2. Anti-inflammatory
12.4.2.1. Prednisolone
12.4.2.2. Tramadol
12.4.2.3. Other Anti inflammatory
12.4.3. CNS Agents
12.4.3.1. Potassium Bromide
12.4.3.2. Gabapentin
12.4.3.3. Other CNS agents
12.4.4. GI Drugs
12.4.4.1. Apomorphine
12.4.4.2. Ursodiol
12.4.4.3. Cisapride
12.4.4.4. Other GI Drugs
12.4.5. Others
12.4.5.1. Methimazole
12.4.5.2. Other drugs
12.5. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Animal Type, 2017–2030
12.5.1. Companion Animal
12.5.1.1. Dogs
12.5.1.2. Cats
12.5.1.3. Others
12.5.2. Livestock Animal
12.6. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2030
12.6.1. Capsule
12.6.2. Solution
12.6.3. Powders
12.6.4. Suspension
12.6.5. Others
12.7. Latin America Animal Drug Compounding Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2030
12.7.1. Oral
12.7.2. Injectable
12.7.3. Topical
12.7.4. Rectal
12.7.5. Ocular
12.8. Middle East & Africa Animal Drug Compounding Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
12.8.1. GCC Countries
12.8.2. South Africa
12.8.3. Rest of Middle East & Africa
13. Competitive Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Company Profiles
13.2.1. Wedgewood Pharmacy
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. Strategic Overview
13.2.1.4. SWOT Analysis
13.2.2. Triangle Compounding Pharmacy
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. Strategic Overview
13.2.2.4. SWOT Analysis
13.2.3. Davis Islands Pharmacy
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. Strategic Overview
13.2.3.4. SWOT Analysis
13.2.4. Custom Med Compounding Pharmacy
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. Strategic Overview
13.2.4.4. SWOT Analysis
13.2.5. Central Compounding Center South
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. Strategic Overview
13.2.5.4. SWOT Analysis
13.2.6. Wellness Pharmacy of Cary
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. Strategic Overview
13.2.6.4. SWOT Analysis
13.2.7. Caringbah Compounding Pharmacy
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. Strategic Overview
13.2.7.4. SWOT Analysis
13.2.8. Millers Pharmacy
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. Strategic Overview
13.2.8.4. SWOT Analysis
13.2.9. Smith's Pharmacy
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Product Portfolio
13.2.9.3. Strategic Overview
13.2.9.4. SWOT Analysis
13.2.10. Specialist Compounding Pharmacy Pte Ltd.
13.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.10.2. Product Portfolio
13.2.10.3. Strategic Overview
13.2.10.4. SWOT Analysis
13.2.11. Tache Pharmacy
13.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.11.2. Product Portfolio
13.2.11.3. Strategic Overview
13.2.11.4. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers